I
Invicta Medical
Operates as a medical technology company that develops therapies for sleep apnea
About Invicta Medical
Established in 2012, Invicta Medical, which has been rebranded as Restera, is a clinical-stage medical technology firm positioned to address the significant market for sleep apnea therapies. The company was founded by Steven Kent and Hal Kent. Rick O'Connor currently serves as the CEO.
The company is focused on developing treatments for obstructive sleep apnea (OSA), a condition affecting an estimated one billion people worldwide, with a significant number remaining undiagnosed. The economic burden of untreated sleep apnea in the United States alone is estimated at $150 billion annually due to associated health conditions and loss of productivity. Restera targets the shortcomings of existing therapies, such as CPAP machines, which suffer from low patient compliance rates due to their cumbersome and intrusive nature.
Restera's primary offering is an intelligent neurostimulation system, which is described as the world's first and only injectable sleep apnea therapy. This system involves a minimally invasive procedure, taking approximately five to ten minutes, where a small, flexible device is injected near the hypoglossal nerve without scalpels or surgery. The implant stimulates the genioglossus muscle, moving the tongue forward to keep the airway open during sleep. The platform includes options for a traditional implantable power source or a wireless, fully injectable device without an onboard battery. This approach allows for the treatment of a broad range of patients, including those with a high BMI or different types of airway collapse.
The company has a strong intellectual property portfolio with 35 patents and patents pending. Clinical data from six studies involving 65 patients has demonstrated a significant reduction in the Apnea-Hypopnea Index (AHI) on the first night of therapy, a notable improvement over existing treatments. To date, Invicta Medical has raised a total of $73.3 million over five funding rounds, with the latest being a Series C round of $25 million in April 2023. The company is seeking further funding to complete feasibility studies and aim for a commercial launch.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| OtherOther financing | May 2024 | $0 | — | MedTech Innovator | ↗ |
| LATE VC✓Equity / VC | Oct 2022 | $18M | $105M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Invicta Medical is 2.5K monthly website visits, up 635.3% over the last three months. Invicta Medical's team declined 27.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Invicta Medical in the San Jose ecosystem
The Invicta Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
R Ventures
Series A4 investors entered at this stage
Thiel Capital
GreatPoint Ventures
Eclipse Ventures
Bonit Capital
Other known investors5 additional known investors
MedTech Innovator
DNS Capital
Grayson Judge
Mike Masterson
Robin Farmanfarmaian
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Invicta Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Invicta Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









